|
⚲
|
| Afferent Pharmaceuticals Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001476010 |
| Sale | 2009-12-09 ($23.0 M Offered, $3.0 M Sold) |
| Fund | |
| Phone | 6175852000 |
| Address | c/o Third Rock Ventures, LP Boston, 02116 |
| Source | [EDGAR] |
| Fund AUM and Sold ($M) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| Kevin Starr | |
| David Neafus | |
| Arthur Pappas | |
| Jesse Treu | |
| Liam Ratcliffe | |
| Mitchell Bloom |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Purvi Ventures I, LP
✚
|
0.0 | |
|
PVP Fund IV, L.P.
✚
|
0.0 | |
|
Pyle Jeremy P.
✚
|
0.0 | |
|
Pyne Christopher W
✚
|
0.0 | |
|
Pyontek Richard Guy
✚
|
0.0 | |
|
Qamar Huma
✚
|
0.0 | |
|
Q BCSP 9 1000-1100 REIT LLC
✚
|
0.0 | |
|
QHP Orange Co-Invest II, L.P.
✚
|
0.0 | |
|
QIC Ballston Common Office REIT Inc.
✚
|
0.0 | |
|
Purposive Growth Secured Income Fund, LLC
✚
|
0.0 |